15-amino-4-7-10-13-tetraoxapentadecanoic-acid and HIV-Infections

15-amino-4-7-10-13-tetraoxapentadecanoic-acid has been researched along with HIV-Infections* in 1 studies

Trials

1 trial(s) available for 15-amino-4-7-10-13-tetraoxapentadecanoic-acid and HIV-Infections

Article	Year
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG Scientific reports, 2017, 08-25, Volume: 7, Issue:1 Topics: Adolescent; Adult; Animals; Cells, Cultured; Cholesterol; Cohort Studies; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Resistance, Viral; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Mice; Middle Aged; Mutagenesis, Site-Directed; Peptide Fragments; Placebo Effect; Polyethylene Glycols; Recombinant Fusion Proteins; T-Lymphocytes; Viral Load; Young Adult	2017

Article

Year

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG

Scientific reports, 2017, 08-25, Volume: 7, Issue:1

Topics: Adolescent; Adult; Animals; Cells, Cultured; Cholesterol; Cohort Studies; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Resistance, Viral; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Mice; Middle Aged; Mutagenesis, Site-Directed; Peptide Fragments; Placebo Effect; Polyethylene Glycols; Recombinant Fusion Proteins; T-Lymphocytes; Viral Load; Young Adult

2017